Plasma ctDNA testing for EGFR mutations in advanced NSCLC is an early success story: it enables targeted therapy (EGFR tyrosine kinase inhibitors) even when tissue samples are unavailable or insufficient. This evidence concerns the gene EGFR and non-small cell lung carcinoma.